Merck’s cardiopulmonary pipeline is poised to deliver eight potential approvals over the next eight years, bolstering the company’s pipeline and revenue.
Merck’s Acceleron Integration To Take Out 143 Jobs in Cambridge, MA
Anemia, Blockbusters, Blood Vessels, Business, Cambridge, Clinical Trials, Committee for Medicinal Products for Human Use (CHMP), Erythroid maturation agents, First-In-Class, Job Cuts, Keytruda, Massachusetts, Pulmonary Arterial Hypertension, R&D, Royalties, Therapeutics, Transforming Growth Factor-beta (TGFb)Merck announced that the company will lay off 170 people from Cambridge, Massachusetts-based Acceleron Pharma, which was acquired during November 2021 for about $11.5 billion.
Merck & Co. is buying Acceleron Pharma Inc. for about $11.5 billion, broadening the company’s portfolio beyond the aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.
Money on the Move: June 30 – July 6
Biology, Business, CAR-T Therapy, Clinical Trials, CRISPR, Financing, Financing, Hereditary Transthyretin Amyloidosis (hATTR), Initial Public Offering (IPO), Nasdaq, Neuromodulation, Pulmonary Arterial Hypertension, R&D, Series A, Series B, Series C Financing, SharesThe IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
United Therapeutics Corporation announced that the company is pursuing additional claims for trade secret misappropriation against Liquidia Technologies Inc. and a former United Therapeutics employee who later joined Liquidia as an executive.
FDA Action Alert: Blueprint, Liquidia, Revance, Rhythm and Merck
Blockbusters, Checkpoint Inhibitors, Clinical Trials, FDA, Frown Lines, LEPR deficiency obesity, LEPR deficiency obesity, Metastatic Rearranged During Transfection (RET) Fusion-Positive Non-Small Cell Lung Cancer (NSCLC), New Drug Applications, New Drug Approvals, Non-Small Cell Lung Cancer, Patent Lawsuits, PD-1/PD-L1 inhibitors, PDUFA, Priority Review Status, Pro-Opiomelanocortin (POMC) Deficiency Obesity, Pulmonary Arterial Hypertension, R&D, Therapeutics, Triple Negative Breast Cancer (TNBC)The U.S. Food and Drug Administration’s PDUFA dates for the last week of November 2020 include a review of Liquidia Technologies’ NDA for LIQ861 for the treatment of pulmonary arterial hypertension (PAH).
Gilead Sciences agreed to pay $97 million to resolve claims from the U.S. government that the company violated the False Claims Act.
Acceleron Pharma and Fulcrum Therapeutics enter 2020 as partners to tackle pulmonary diseases.
PhaseBio Receives FDA Breakthrough Therapy Designation and Licenses GLP-1 Analog to ImmunoForge
Antiplatelet Drugs, Breakthrough Therapy Designation, FDA, FDA/Regulatory, Glucagon-Like Peptide-1 (GLP-1) Analogs, Heart Attacks, Monoclonal Antibodies, Muscle loss, Pulmonary Arterial Hypertension, Sarcopenia, StrokesPhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.
Silver Spring, Maryland-based United Therapeutics announced that the company’ esuberaprost tablet did not meet the primary endpoint in the BEAT Phase III clinical trial in patients with pulmonary arterial hypertension (PAH).